London, UK – 12th November, 2025 – Curaleaf Laboratories, one of the UK’s leading providers of medicinal cannabis products, is pleased to announce a landmark partnership with Australian Natural Therapeutics Group (ANTG), one of Australia’s most respected producers of pharmaceutical-grade medicinal cannabis. Under this agreement, Curaleaf Laboratories will manufacture and distribute ANTG’s range of products across the United Kingdom, significantly expanding access to medicinal cannabis for eligible patients and healthcare professionals.
The partnership combines Curaleaf Laboratories’ state-of-the-art UK manufacturing capabilities and established distribution network with ANTG’s expertise in cultivating and developing consistent, pharmaceutical-grade cannabis formulations. Together, the companies aim to meet the growing demand for safe, effective, and reliably sourced medicinal cannabis products in the UK market, in line with applicable regulation.
“This partnership marks a significant milestone for Curaleaf Laboratories as we continue to deliver on our commitment to support patient access to pharmaceutical-grade, evidence-based cannabis medicines,” said Richard Hodgson, Managing Director, Curaleaf Laboratories. “ANTG’s reputation for excellence and scientific rigor aligns perfectly with our mission to set new standards in product quality and patient care.”
Matt Cantelo, Founder and CEO, ANTG added: “Partnering with Curaleaf Laboratories brings together two organisations dedicated to quality and patient care. This collaboration represents an important step in our international growth strategy and our shared goal of improving patient outcomes through trusted, pharmaceutical-grade cannabis-based medicines.”
The first ANTG products manufactured under this partnership will be available on prescription by clinicians listed on the UK Specialist Register from November 2025.
If you are an interested healthcare professional seeking information on prescribing or ordering, please contact us at info@curaleaflaboratories.co.uk
Patients seeking information from their dispensing pharmacy may visit Curaleaf Pharmacy if applicable. Treatment decisions should be made in consultation with a qualified healthcare professional.
Disclaimer: This press release includes information about cannabis-based products for medicinal use. These products are available in the UK only via prescription from a specialist doctor. This announcement is not intended to promote prescription-only medicines to the public. Treatment decisions should be made by a qualified healthcare professional.
About Curaleaf Laboratories
Curaleaf Laboratories are one of the UK-leading experts in the manufacture and distribution of EU-GMP medical cannabis. With a state-of-the-art MHRA-approved medical cannabis manufacturing facility and a comprehensive quality management system, Curaleaf Laboratories is meeting the growing patient demand for a consistent range of medical cannabis manufactured to EU-GMP standards, with varying novel dosage forms and levels of cannabinoid content.
Part of the Curaleaf International group since 2019, Curaleaf Laboratories has evolved from a well-established specials medicines manufacturer with over a decade of expertise in unlicensed medicines. With that experience, Curaleaf Laboratories is widening access to clinics and pharmacies all across the UK, while leading the market as a trusted manufacturer, distributor and partner.
About ANTG (Australian Natural Therapeutics Group)
Australian Natural Therapeutics Group (ANTG) is a leading Australian producer of pharmaceutical-grade medicinal cannabis, committed to advancing patient care through science, quality, and innovation. Established in 2016, ANTG operates a fully integrated, GMP-certified supply chain and partners with research institutions to support evidence-based development. ANTG’s range of high-quality medicinal cannabis products is available in Australia, New Zealand, Germany, and the United Kingdom.